Dr. Anthony Siegall And His Work To Eliminate Cancer
We live at a time when medical breakthroughs are being made almost weekly. The fight against all forms of cancer is being taken on by many pharmaceutical companies. The treatment methodology has added targeted chemotherapy to the basic treatment of radiation and traditional chemotherapy. These exciting new therapies may, in the not too distant future, provide ways to treat and possibly cure many types of cancer.
One such company making huge strides in cancer treatment is Seattle Genetics. Founded in 1998, its CEO Dr. Clay Siegall has driven his company to excel in new technology. Dr. Siegal is driven by an intense desire to help cancer patients and has made it a priority for his company to concentrate on research and quickly implement any medical breakthroughs.
Dr, Siegall worked for the National Cancer Institute from 1988 to 1991, and then became a Senior Research Investigator for Bristol-Myers Squibb. He soon was promoted to Principal Scientist, and then became a Staff Fellow and Biotechnology Fellow at the National Cancer Institute. In addition to leading Seattle Genetics, Dr. Siegall has more than 70 published scientific articles and 15 patents to his credit.
Under his tutelage, in 2011 the company received FDA approval for the first antibody-drug conjugate (ADCs) ADCETRIS and is now available to patients in 60 countries. In 2016, the FDA granted Breakthrough Therapy Designation for another antibody-drug conjugate, sacituzumab govitecan (try saying that three times fast). This wonder drug is being tested for treatment of a number of cancers, including lung, breast, bladder and pancreatic cancer.
With many new antibody-based cancer therapies in their pipeline, Dr. Siegall may soon realize his dream of conquering cancer.